2020
Kisor DF, Monte AA, Mueller DJ. Evidence-Based Pharmacogenomics Guidelines: Supporting Label and Off-Label Use of Drug-Gene Interaction Data. Pharmacogenomics. 21(7):427-430.
Kisor DF,Bright DR, Smith TR, Wiisanen K. [Book] Pharmacogenomics: Foundations, Competencies and the Pharmacists' Patient Care Process.American Pharmacists Association. Washington DC, 2020.
2019
Hilden M, Bright DR, Christensen H, Kisor DF. Red, Yellow, Green: Stop, Proceed with Caution, or Go with Pharmacogenomics -A Practical Primer for the Consultant Pharmacist. Senior Care Pharm. 34(6):363-369, 2019.
Kisor DF, Farrell CL. Expanding pharmacist and student pharmacist access to genetics/genomics/pharmacogenomics competency education. Med Ed Curr Devel. 2019;https://doi.org/10.1177/2382120519834325.
2018
Kisor DF, Hoefer CC, Decker BS. In Thomas D (ed).Pharmacogenomics and Precision Medicine in: Clinical Pharmacy Education, Practice and Research. 2018. Oxford, UK. 437-452.
Grecco GG, Kisor DF; Sprague JE. Pharmacokinetic data of synthetic cathinones in female Sprague-Dawley rats. Data Brief. 2018;21:1045-1050.
Calinski DM, Kisor DF, Sprague JE. A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics. Psychopharmacology. https://doi.org/10.1007/s00213-018-4985-6, 2018.
Kisor DF, Bodzin AS. Pharmacogenomics in liver transplantation: Testing the recipient and the ex-vivo donor liver. Pharmacogenomics (Published Online 23 May 2018). https://www.futuremedicine.com/doi/10.2217/pgs-2018-0052.
Beckett RD, Kisor DF, Smith T, Vonada B. Systematic evaluation of clinical practice guidelines for pharmacogenomics. Pharmacogenomics. 2018;19(8):693-700. (Published Online 23 May 2018).
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0024.
Hoefer CC, Brick EJ, MS, Savariar A, Kisor DF, Dawson A, Khatri A, Johnson J, Henriksen B. Allelic frequencies of 60 pharmacogene variants assessed within a Burmese Population residing in North East Indiana, U.S. Pharmacogenomics. 19(5):393–399, 2018.
Kisor DF, Calinski DM, Farrell CL. Beyond the didactic lecture: Pharmacogenomics in Pharmacy Education. Per Med. 15(1):9-12, 2018.
2017
Beam T, Loudermilk E, Kisor DF. Pharmacogenetics and Pathophysiology of CACNA1S Mutations in Malignant Hyperthermia. Physiological Genomics. 49(2):81-87, 2017.
Hrometz SL, Say SP. Topic: Sex Hormones. In Ray S (Ed.), Side Effects on Drugs Annual Volume 39. Elsevier B.V., 2017.
Bright DR, Greco AJ, Langerveld A, Kisor DF. Clinical Implementation of Personalized Medicine in Community Pharmacies: Considerations for Clinicians. Per Med. 14(6):471-475, 2017.
Grecco GG, Kisor DF, Magura JS, Sprague JE. Impact of common clandestine structural modifications on synthetic cathinone "bath salt" pharmacokinetics. Tox App Pharmacol 328:18-24, 2017.
Bottorff MM, Bright DR, Kisor DF. Should pharmacogenomic evidence be considered in clinical decision-making? Examples from cardiology. Pharmacotherapy 37(9):1005-1013, 2017.
Roederer MW, Kuo GM, Kisor DF, Frye R, Hoffman JM, Jenkins J, Weitzel KW. Pharmacogenomics Competencies in Pharmacy Practice: A Blueprint for Change. J Am Pharm Assoc. 57(1):120-125, 2017.
2016
Calinski DM, Kisor DF. An Interdisciplinary Experience focused on Pharmacogenetics: Engaging pharmacy and physician assistant students in conversations about antiplatelet therapy with respect to CYP2C19 genotype. Innov Pharm. 7(1): Article 1, 2016.
Hrometz SL, Ebert JA, Grice KE, Nowinski SM, Mills EM, Myers BJ, Sprague JE. Potentiation of Ecstasy-induced hyperthermia and FAT/CD36 expression in chronically exercised animals. Temperature.3(4): 557–566, 2016.
Hrometz SL, Topic: Sex Hormones. In Ray S (Ed.), Side Effects on Drugs Annual Volume 38. 433-442. Elsevier B.V., 2016.
Trovinger SN, Hrometz SL, Keshsiyan S, Ray SD. Topic: Insulin and Other Hypoglycemic Drugs. In Ray S (Ed.), Side Effects on Drugs Annual Volume 38. 453-462. Elsevier B.V., 2016.
Maroney M, Liu MT, Smith T, Thomas KL. Lithium. In: Ray SD, ed. Side Effects of Drugs Annual Volume 38. 21-28. Elsevier B.V., 2016.
Smith TR, Wagner ML. Parkinson disease. Chapter 33. In: Marie A. Chisholm-Burns, Terry L. Schwinghammer, Barbara G. Wells, Patrick M. Malone, Jill M. Kolesar, Joseph T. DiPiro (Ed.), Pharmacotherapy Principles and Practice, 4th Edition. McGraw-Hill Companies. New York, 2016.
Smith TR, Kearney E, Hulick PJ, Kisor DF. History repeats itself: the family medication history and pharmacogenomics. Pharmacogenomics. 17(7):669-78, 2016.
Kisor DF, Bright DR, Manion CR, Smith TR. Pharmacogenomics: Overview of Applications and Relation to Infusion Therapy. J Infus Nurs. 39(3):139-148, 2016.
Weitzel KW, Aquilante CL, Johnson S, Kisor DF, Empey PE. Educational strategies to provide pharmacogenomics-based care. Am J Health Syst Pharm. 73:1986-98, 2016.
Banks ML, Smith DA; Kisor DF; Poklis JL. Relationship between discriminative stimulus effects and plasma methamphetamine and amphetamine levels of intramuscular methamphetamine in male rhesus monkeys. Pharmacol Biochem Behav. 141:58-65, 2016.
2015
Kisor DF, Smith HE, Grace E, Johnson SG, Weitzel KW, Farrell CL. The DNA of pharmacy Education. AACP. https://www.aacp.org/sites/default/files/2017-10/The_DNA_of_Pharmacy_Education-CAPE_Outcomes_and_Pharmacogenomics_2015.pdf, 2015
Calinski DM, Zhang H, Hollenberg PF. Hydroxylation and N-dechloroethylation of Ifosfamide and Deuterated Ifosfamide by Human Cytochrome P450s and their Common Polymorphisms. Drug Metab Disp. 43(7):1084-90, 2015.
Bright DR; Calinski DM, Kisor DF. Pharmacogenetic Considerations in the Elderly Patient. Consult Pharm. 30(4), 228-39, 2015.
Smith TR, Liu MT, Maroney, ME. 2015. Lithium. Chapter 3. In: Sidhartha D. Ray (Ed.), Side Effects of Drugs Annual Vol 37. Elsevier B.V., 2015.
Smith TR. Implementing Second-Line and third-Line Therapies for Attention Deficit Hyperactivity Disorder: The Case of the Unfocused Student. In: Chavez B, Grady SE, McGuire JM, Nelson LA, editors. Psychiatric Pharmacotherapy Case Series. Lincoln (NE): College of Psychiatric and Neurologic Pharmacists. 22p. Available from: http://cpnp.org/ed/case/2015/adhd-2, 2015.
Kisor DF, Bright DR, Chen J, Smith TR. Academic and Professional Pharmacy Education: A Pharmacogenomics Certificate Training Program. Pers Med. 12(6):563-573, 2015.
Bright DR, Kisor DF, Smith A, Conaway M, Yu M. Implementation of a Pharmacogenetic Management Service for Post-Myocardial Infarction Care in a Community Pharmacy. Pers Med. 12(4), 319-325, 2015.
2014
Hrometz SL. (2014) Topic: Benign Prostate Hypertrophy. In Mason B, Parker D & Lott RS (Eds.), Capstone Pharmacy Review (pp 627-631). Jones & Barlett Learning.
Hrometz SL. Topic: Glaucoma. In Mason B, Parker D & Lott RS (Eds.), Capstone Pharmacy Review (pp 632-638). Jones & Bartlett Learning, Burlington, MA, 2014.
Hrometz SL. Topic: Urinary Incontinence. In Mason B, Parker D & Lott RS (Eds.), Capstone Pharmacy Review (pp 639-644). Jones & Bartlett Learning, Burlington, MA, 2014.
Hrometz SL. Topic: Osteoporosis. In Mason B, Parker D & Lott RS (Eds.), Capstone Pharmacy Review (pp 644-650). Jones & Bartlett Learning, Burlington, MA, 2014.
Hrometz SL. Topic: Special Considerations for the Geriatric Patient. In Mason B, Parker D & Lott RS (Eds.), Capstone Pharmacy Review (pp 650-655). Jones & Bartlett Learning, Burlington, MA, 2014.
Smith TR. Implementing Second-Line and Third-Line Restless Legs Syndrome Therapies: The Case of the Tired Retiree. In: Grady SE, McGuire JM, Nelson LA, Rappa L, editors. Psychiatric Pharmacotherapy Case Series. Lincoln (NE): College of Psychiatric and Neurologic Pharmacists; 2014. 12 p. Available from: http://cpnp.org/ed/case/2014/sleep-2, 2014.
Fuentes DG, Caudill W, Henriksen JA, Smith TR. The CAPE Outcome Revisions Should Not Require Drastic Changes to Pharmacy Curricula. Am J Pharm Ed. 78 (1), 2014.
Westervelt P, Cho K, Bright DR, Kisor DF. Drug-Gene Interactions: Inherent Variability in Maintenance Dose Requirements. Pharm Ther. 39(9), 630-637, 2014.
Bova K, Bova S, Hill K, Dixon M, Ivankovic D, Kisor DF. Introducing Pharmacogenetics and Personalized Medicine via a Weblog. Innov Pharm. 5(2);1-11, 2014.
Kisor DF, Bright DR, Conaway MM, Bouts BA, Gerschutz G. Pharmacogenetics in the Community Pharmacy: Thienopyridine Selection Post Coronary Artery Stent Placement. J Pharm Prac. 27(4);416-419, 2014.
2013
Lin HL, D'Agostino J, Kenaan C, Calinski D, Hollenberg P F. The Effect of Ritonavir on Human CYP2B6 Catalytic Activity: Heme Modification Contributes to the Mechanism-Based Inactivation of CYP2B6 and CYP3A4 by Ritonavir. Drug Metab Dispos, 41(10),1813-1824, 2013.
Smith TR. Women and depression – Does gender matter? US Pharm. 2013; 38(9):36-39. Available at: http://www.uspharmacist.com/content/c/43010/?t=women%27s_health, 2013.
Kisor DF, Kane, MD, Talbot JT, Sprague JE. Pharmacogenetics, Kinetics and Dynamics for Personalized Medicine. 1st Ed. Jones and Bartlett Learning. Burlington, MA. 2013.
Linn D, Murray A, Smith TR, Fuentes D. Clinical Considerations for the Management of Pediatric Patients with Attention-Deficit/Hyperactivity Disorder. Ment Health Clin. 2013;2(11):91. Available at: http://cpnp.org/resource/mhc/2013/05/clinical-considerations-management-pediatric-patients-attention, 2013.
Kisor DF. Making personalized medicine an expectation of pharmacy students. Pers Med. 10(1):5-8, 2013.
Shields KM, Sobota KF, Kroustos KR, Bright DR, North CL, Kisor DF. Implementation and evaluation of a student-led, online, longitudinal outpatient case elective. Curr Pharm Teach Learn. 5(5);351-357, 2013.
Kisor DF, Smith AJ. Therapeutic Actions and the Genetic Code: Examples of the application of pharmacogenetics. Ohio Pharmacist. 62(12):7-12, 2013.
Kisor DF, Kroustos K. Pharmacogenomics in women's health. U.S. Pharmacist. 38(9):70-80, 2013.
Kisor DF, Sprague JE. The application of drug dosing guidelines based on preemptive genetic testing. Spec Pharm Times. 4(3), 2013.
Kisor DF, Talbot JN, Stockert AL, Smith A. Exploring a laboratory model of pharmacogenetics as applied to clinical decision making. Innov Pharm. 4(2);1-12, 2013.
2012
Hrometz SL. Oral tranexamic acid (Lysteda®) for cyclic heavy menstrual bleeding. Ann of Pharmacother. 46(7-8):1047-1053, 2012.
Smith TR, Wagner ML, Liu MT. Effective Drug Therapy for Epilepsy. Pharmacy Times Health System Edition. Published online May 2012: http://www.pharmacytimes.com/publications/health-system-edition/2012/May-2012/Effective-Drug-Therapy-for-Epilepsy, 2012.
Kisor DF, Munro C, Loudermilk E. Pharmacogenomics and the most commonly prescribed drugs of 2011. Pharm Times. 78(12):85-96, 2012.
2011
Chung KY, Rasmussen SG, Liu T, Li S, DeVree BT, Chae PS, Calinski D, Kobilka BK, Woods VL, Sunahara R K. Conformational changes in the G protein Gs induced by the β2 adrenergic receptor. Nature. 477(7366), 611-5, 2011.
Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, Calinski D, Mathiesen JM, Shah ST, Lyons JA, Caffrey M, Gellman SH, Steyaert J, Skiniotis G, Weis WI, Sunahara R K, Kobilka BK. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature. 477(7366), 549-55, 2011.
Rojeab Y, Martin S, White R, Montenery S, McWilliams M, Walker M, Kisor D. In vitro dissolution and pilot pharmacokinetic studies of acetylsalicylic acid from an orally disintegrating tablet formulation of low-dose aspirin. Int J Med Clin Res. 2:72-77, 2011.
Westfield GH, Rasmussen SG, Su M, Dutta S, DeVree BT, Chung KY, Calinski D, Velez-Ruiz G, Oleskie AN, Pardon E, Chae PS, Liu T, Li S, Woods VL, Steyaert J, Kobilka BK, Sunahara RK, Skiniotis G. Structural flexibility of the Gαs α-helical domain in the β2-adrenoceptor Gs complex. Proc Natl Acad Sci U S A. 108 (38),16086-91, 2011.
Calinski DM, Edwald E, Sunahara RK. Use of Model Membranes to Study GPCR Signaling Units: Insights into Monomers and Oligomers in G Protein-Coupled Receptors: From Structure to Function. Royal Society of Chemistry: London, England, 2011.
Hrometz SL, Thatcher KE, Ebert JA, Mills EM, Sprague JE. Identification of a possible role for atrial natriuretic peptide in MDMA-induced hyperthermia. Tox Lett. 206:234-237, 2011.
2010
Ling X, Calinski D, Chanan-Khan AA, Zhou M, Li F. Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. J Exp Clin Cancer Res. 29, 8, 2010.
Roecker AM, Stockert A, Kisor DF. Nelarabine in the treatment of refractory T-cell malignancies. Clin Med Insights Oncol. 4:133-151, 2010.
Likovich M, Derr A, Kane M, Kisor DF, Sprague JE. Personalized medicine and the future of pharmacy practice. Pharm Times. 76(4), 2010.
2009
Hrometz SL, Gates VA. Review of available infertility treatments. Drugs of Today. 45(4):275-291, 2009.
Collins GT, Calinski DM, Newman AH, Grundt P, Woods JH. Food restriction alters N'-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride (pramipexole)-induced yawning, hypothermia, and locomotor activity in rats: evidence for sensitization of dopamine D2 receptor-mediated effects. J Pharmacol Exp Ther. 325 (2), 691-7, 2009.
Reilly KM, Kisor DF. Profile on nelarabine: Use in the treatment of T-cell acute lymphoblastic leukemia. OncoTargets and Therapy. 2:219-228, 2009.
2008
Hrometz SL, Shields KM. Role of Ambrisentan in the Management of Pulmonary Hypertension. Ann of Pharmacother. 42(11):1653-9, 2008.
Colaizzi JL, Smith TR. Medication Reconciliation: Implications for Community, Hospital and Consultant Pharmacists. NJ J Pharm. 82:24-25, 2008.
2007
Banks ML, Sprague JE, Kisor DF, Czoty PW, Nichols DE, MA Nader. Ambient temperature effects on 3,4-methylenedioxymethamphetamine (MDMA)-induced thermodysregulation and pharmacokinetics in male monkeys. Drug Metab Disp. 35:1840-1845, 2007.
2006
Hrometz SL, Shields KM. Sildenafil Citrate for Treatment of Pulmonary Hypertension. Drugs of Today. 42(12):771-84, 2006.
Kisor DF. Nelarabine. Drugs of Today. 42(7):455-465, 2006.
Allison JA, Roecker A, Kisor DF. Nelarabine. Fut Onc. 2(4)441-448, 2006.
2005
Li X, Harrell RA, Handler AM, Beam T, Hennessy K, Fraser MJ. PiggyBac internal sequences are necessary for efficient transformation of target genomes. Insect Molecular Biology. 14(1),17-30, 2005.
Shields KM, Hrometz SL. Use of Phosphodiesterase Inhibitors for Female Sexual Dysfunction. Ann of Pharmacother. 40(5):931-4, 2005.
Kisor DF. Nelarabine: A nucleoside analog with efficacy in T-cell and other leukemias. Ann Pharmacother. 39:1056-1063, 2005.
Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, Lager JJ, Stephens C, Levin G, Krenitsky T, Elion G, Mitchell BS. A phase I study of 2-amino-9-Beta-D-arabinofuranosyl-6-methoxy-9H purine (506U78[Nelarabine]) administered on a consecutive five day schedule in children and adults with refractory hematological malignancies. J Clin Onc. 23(15):3396-3403, 2005.
2004
Hrometz SL, Brown AW, Nichols D E, Sprague JE. 3-4-Methylenedioxymethamphetamine (MDMA, Ecstasy)-Mediated Production of Hydrogen Peroxide in an In Vitro Model: The Role of Dopamine, the Serotonin-Reuptake Transporter, and Monoamine Oxidase-B. Neuroscience Lett. 367:56-59, 2004.
2000
Kisor, DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T, Keating MJ, and Gandhi V. The pharmacokinetics of Nelarabine and 9-Beta-D-Arabinofuranosyl guanine in pediatric and adult patients receiving nelarabine during a phase I study of Nelarabine for the treatment of refractory hematological malignancies. J Clin Onc. 18:995-1003, 2000.
1999
Beam TA, Bauser CA, Fraser MJ. Identification of terminal repeat binding proteins (TRBPs) from Lepidopterans that recognize the ends of TTAA-specific transposons piggyBac and tagalong. Insect Molecular Biology. 8(2):223-30, 1999.
Kisor DF, Schmith VD. Clinical pharmacokinetics of cisatracurium. Clin Pharmacokin. 36:27-40, 1999.
Pabelick CM, Hrometz SL, Prakash, YS, Warner DO, Sieck GC. Comparison of sevoflurane and isoflurane effects on calcium regulation in airway smooth muscle. Anesthesiology. 3A:A434, 1999.
Hrometz SL, Edelmann SE, McCune DF, Olges JR, Hadley RW, Perez DM, Piascik MT. Expression of Multiple alpha1-Adrenoceptors on Vascular Smooth Muscle: Correlation with the Regulation of Contraction. J Pharmacol Exp Ther. 290:452-463, 1999.
1998
Gandhi V, Plunkett W, Rodriguez CO, Kisor, DF, Mitchell BS, Kurtzberg J, Keating MJ. A phase I study of GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response. J Clin Onc. 16;3607-3615, 1998.
1997
Beam TA, Lobo N, Fraser MJ. Analysis of the cis-acting DNA elements required for piggyBac transposable element excision. Molecular and General Genetics. 255:605-610, 1997.
Piascik MT, Hrometz SL, Edelmann SE, Guarino RD, Hadley RW, Brown RD. Immunocytochemical Localization of the Alpha-1B Adrenergic Receptor and the Contribution of This and the Other Subtypes to Vascular Smooth Muscle Contraction: Analysis with Selective Ligands and Antisense Oligonucleotides. J Pharmacol Exp Ther. 283:854-868, 1997.
Jewell, RC, Khor SP, Kisor DF, Krueger KA, Wargin WA. Pharmacokinetics of RheothRx injection in health male volunteers. J Pharm Sci. 86:808-812, 1997.
1996
Beam TA, Bauser CA, Fraser MJ. Excision of the piggyBac transposable element in vitro is a precise event that is enhanced by the expression of its encoded transposase. Genetica. 98: 33-41, 1996.
Beam TA, Bauser CA, Nicole M. Principe, Fraser MJ. PCR analysis of insertion site specificity, transcription, and structural uniformity of the lepidopteran transposable element IFP2 in the TN-368 cell genome. Genetica. 97: 127-139, 1996.
Bauser CA, Beam TA, Fraser MJ. Characterization of hitchhiker, a transposon insertion frequently associated with Baculovirus FP mutants derived upon passage in the TN-368 cell line. Virology. 216: 235-237, 1996.
Fraser MJ, Cisczcon T, Beam TA, Bauser CA (1996). Precise excision of TTAA-specific Lepidopteran transposons TFP3 and IFP2 from the Baculovirus genome in cell lines from two species of lepidoptera. Insect Molec Biol. 5(2): 141-151, 1996.
Schmith VD, Phillips L, Kisor DF, Fiedler-Kelly J, Weatherley BC. Pharmacokinetics/ Pharmacodynamics of cisatracurium in healthy adult patients. Cur Opin Anesth. 9:s9-s15, 1996.
De Wolf AM, Freeman JA, Scott VL, Tullock W, Smith DA, Kisor DF, Kerls S, Cook DR. The pharmacokinetics and pharmacodynamics of 51W89 in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth. 76:624-628, 1996.
Lien CA, Schmith VD, Belmont MR, Abalos A, Kisor DF, Savarese JJ. Pharmacokinetics of 51W89 in patients receiving nitrous oxide-opioid-barbiturate anesthesia. Anesthesiology. 84:300-308, 1996.
Kisor DF, Schmith VD, Wargin WA, Ornstein E, Cook DR. The importance of the organ independent elimination of cisatracurium. Anesth Analg. 83:1065-1071, 1996.
1995
Kwon B, Jang I, Broxmeyer H, Cooper S, Jenkins N, Gilbert D, Copeland N, Beam T, Fraser MJ. A novel chemokine, macrophage inflammatory protein-related protein-2 inhibits colony formation of bone marrow myeloid progenitors. J Immunology. 155: 2661-2667, 1995.
1994
Martin M, Manez R, Linden P, Estores D, Torre-Cisneros J, Kusne S, Ptachcinski R, Kisor D, Ondick L, Felser I, Irish W, Fung J, Starzl T. A short early course of ganciclovir prevents both cytomegalovirus infection and disease in adult liver transplant patients. Transplantation. 58:779-785, 1994.
1993
Kisor DF, Frye RF, Kudsk KA. Estimation of the hepatic extraction ratio of indocyanine green in swine. Clin Sci. 84:681-685, 1993.
Watling SM, Kisor DF. Population pharmacokinetics: Development of a medical intensive care unit-specific gentamicin dosing nomogram. Annal Pharmacother. 27:151-154, 1993.
1992
Kisor DF, Watling SM, Zarowitz BJ, Jelliffe RW. Population pharmacokinetics of gentamicin in patients with indicators of malnutrition: the use of a new nonparametric expectation maximization (NPEM) algorithm. Clin Pharmacokin. 23:62-68, 1992.
Kudsk KA, Kisor DF, Waters B, Mirtallo JM, Campbell AJ, Wooding-Scott RA. Effect of nutritional status upon organic anion clearance by the swine liver. Surgery. 111:188-194, 1992.
1990
Kisor DF, Wooding-Scott RA. Effect of theophylline on estimated hepatic blood flow. Pharmacotherapy. 10(6):406-409, 1990.
Kisor DF, Mehta V, Vieira-Fattahi S, Sterchele JA. Practical considerations in therapeutic drug monitoring. Postgrad Med. 87(4):239-246, 1990.